가축 의학 시장 : 세계 예측(2026-2032년)

The Livestock Medicine Market is projected to grow by USD 30.72 billion at a CAGR of 5.71% by 2032.

Livestock medicine is becoming a strategic pillar of resilient animal agriculture as producers, veterinarians, regulators, and food-chain stakeholders respond to rising demand for safe animal protein, persistent transboundary animal disease risks, antimicrobial resistance, and climate-related stress on herds and flocks. The field spans preventive healthcare, vaccines, parasiticides, anti-infectives, diagnostics, reproductive health, nutritional therapeutics, biosecurity, and herd health management across cattle, swine, poultry, sheep, goats, and aquaculture-adjacent production systems. Verified public-health guidance from global animal health authorities consistently emphasizes prevention, surveillance, vaccination, responsible antimicrobial use, and rapid outbreak response as essential to protecting animal welfare and food security. In this environment, livestock medicine is shifting from episodic treatment toward integrated, evidence-led population medicine, supported by diagnostics, digital records, farm-level monitoring, and stronger veterinary oversight.

Transformative Shifts in the Livestock Medicine Landscape

The livestock medicine landscape is being reshaped by four major forces: disease pressure, regulatory modernization, sustainability expectations, and digital transformation. Outbreaks of avian influenza, African swine fever, foot-and-mouth disease, lumpy skin disease, and endemic respiratory and enteric infections continue to reinforce the value of vaccination, surveillance, and biosecurity. At the same time, antimicrobial stewardship policies are tightening across many jurisdictions, encouraging veterinarians and producers to adopt diagnostics-led treatment, improved husbandry, vaccination programs, and alternatives that reduce unnecessary antimicrobial exposure. Food retailers, processors, and export markets are also placing greater emphasis on traceability, animal welfare, residue control, and environmental performance. These shifts are accelerating demand for integrated herd health programs, cold-chain reliability for biologics, point-of-care diagnostics, disease monitoring systems, and preventive medicine protocols that align productivity with public health and sustainability goals.

Cumulative Impact of Artificial Intelligence on Livestock Medicine

Artificial intelligence is beginning to alter how livestock medicine is delivered, particularly in disease detection, precision treatment, biosecurity monitoring, and veterinary decision support. AI-enabled image recognition, acoustic monitoring, wearable sensors, and computer vision can help identify early signs of lameness, respiratory distress, heat stress, abnormal feeding behavior, and reproductive events before clinical losses escalate. Predictive analytics can combine veterinary records, weather data, movement data, production metrics, and laboratory results to flag herd-level disease risks and guide targeted interventions. AI also supports antimicrobial stewardship by helping veterinarians evaluate treatment histories, susceptibility results, withdrawal periods, and recurrence patterns. However, adoption depends on data quality, interoperability, farm connectivity, cybersecurity, veterinary validation, and ethical governance. The greatest value is expected where AI augments rather than replaces clinical judgment, enabling earlier intervention, stronger surveillance, and more efficient use of vaccines, diagnostics, and therapeutics.

Key Regional Insights Across Livestock Medicine

Asia-Pacific is a critical center for livestock medicine due to its large and diverse animal protein systems, ranging from intensive poultry and swine operations to smallholder dairy and mixed farming. The region faces recurring pressure from avian influenza, swine diseases, parasitic infections, and zoonotic disease concerns, making vaccination, diagnostics, biosecurity, and veterinary access central priorities. North America is characterized by advanced veterinary infrastructure, strong regulatory oversight, established herd health programs, and broad use of diagnostics, vaccines, prescription animal medicines, and digital production records, with antimicrobial stewardship and traceability shaping purchasing and treatment practices. Latin America remains highly important for cattle, poultry, and swine production, with Brazil and Mexico reinforcing demand for disease prevention, parasite control, reproductive health, and export-compliant residue management. Europe places strong emphasis on animal welfare, reduced antimicrobial dependence, pharmacovigilance, and preventive veterinary medicine, supported by strict food-safety and veterinary medicine regulations. The Middle East prioritizes food security, high-value dairy, poultry, camel, and small ruminant health, with heat stress, import dependence, and biosecurity influencing veterinary product and service needs. Africa presents a dual landscape of commercial livestock expansion and smallholder dependence, where livestock medicine is closely tied to food security, rural livelihoods, vaccination campaigns, parasite control, and improved access to veterinary diagnostics and cold-chain distribution.

Key Group Insights Across Livestock Medicine

ASEAN livestock medicine priorities are shaped by dense poultry and swine production, smallholder farming, tropical disease pressure, and the need for stronger surveillance and biosecurity across cross-border value chains. GCC countries emphasize veterinary solutions that support food security, intensive dairy and poultry systems, camel and small ruminant health, and adaptation to heat stress and water scarcity. The European Union continues to influence global livestock medicine standards through stringent rules on veterinary medicinal products, antimicrobial use, animal welfare, residue monitoring, and farm-to-fork safety, encouraging preventive care and documented treatment protocols. BRICS economies combine large livestock populations, expanding animal protein consumption, and significant disease-management needs, making vaccines, anti-parasitics, diagnostics, and herd health services central to productivity and resilience. G7 countries are prominent in high-standard veterinary governance, advanced diagnostics, surveillance systems, antimicrobial stewardship, and innovation adoption, with strong emphasis on One Health alignment. NATO member states, while diverse in livestock systems, share heightened attention to supply-chain resilience, biosecurity, food security, and disease preparedness, particularly where agricultural continuity intersects with national resilience planning.

Key Country Insights Across Livestock Medicine

The United States has a highly developed livestock medicine ecosystem supported by large-scale cattle, swine, poultry, and dairy operations, veterinary prescription oversight, disease surveillance, and growing adoption of digital herd health tools. Canada emphasizes biosecurity, responsible antimicrobial use, dairy and beef herd health, and strong food-safety compliance across integrated production chains. Mexico's livestock medicine priorities include cattle and poultry health, vaccination, parasite control, and trade-linked disease monitoring. Brazil is a major animal protein producer where livestock medicine is closely tied to beef, poultry, swine, reproductive performance, endemic disease control, and export-market compliance. The United Kingdom maintains strong standards in animal welfare, veterinary oversight, residue control, and antimicrobial stewardship, while Germany and France place strong emphasis on regulated veterinary medicine use, preventive livestock health, diagnostics, and food-chain safety. Russia's livestock medicine needs are influenced by large poultry, swine, and cattle production systems, disease prevention, and domestic food security priorities. Italy and Spain combine intensive livestock production with strict European veterinary regulations, supporting demand for vaccines, biosecurity, and animal welfare-compliant treatment. China is a major driver of livestock health transformation due to intensive swine, poultry, dairy, and aquaculture-linked protein systems, with strong focus on disease control, vaccination, and biosecurity after major animal disease disruptions. India's livestock medicine landscape is shaped by one of the world's largest dairy animal bases, smallholder production, vaccination programs, parasitic disease management, and growing veterinary access needs. Japan prioritizes high-biosecurity livestock systems, food safety, traceability, and advanced veterinary care, while Australia emphasizes extensive cattle and sheep production, disease freedom status, parasite management, and export assurance. South Korea's livestock medicine priorities include high-density swine and poultry production, rapid disease response, vaccination, and technologically enabled farm monitoring.

Actionable Recommendations for Livestock Medicine Leaders

Industry leaders should prioritize preventive livestock healthcare strategies that combine vaccination, diagnostics, parasite control, reproductive management, nutrition, and biosecurity into integrated herd and flock health programs. Veterinary medicine portfolios should align with antimicrobial stewardship by supporting diagnostics-led treatment, susceptibility testing, withdrawal-period compliance, and alternatives that reduce avoidable antimicrobial exposure. Investment in cold-chain integrity, last-mile veterinary access, and training for farm personnel can improve outcomes, especially in regions with fragmented production systems. Digital tools should be adopted where they provide measurable clinical value, such as early disease detection, treatment documentation, traceability, and welfare monitoring. Leaders should also strengthen pharmacovigilance, regulatory compliance, and residue-management systems to support food safety and export readiness. Collaboration with veterinarians, producer groups, laboratories, universities, and public agencies can enhance surveillance, improve outbreak preparedness, and accelerate adoption of evidence-based livestock medicine practices.

Research Methodology

This executive summary is developed through a secondary research-led methodology focused on verified, data-backed information from public veterinary authorities, animal health regulators, food-safety agencies, peer-reviewed scientific literature, agricultural policy sources, and internationally recognized One Health guidance. The analysis emphasizes qualitative assessment of disease dynamics, regulatory direction, antimicrobial stewardship, animal welfare standards, technology adoption, and regional livestock production characteristics. Sources are evaluated for credibility, recency, methodological transparency, and relevance to livestock medicine across species and geographies. The approach intentionally excludes market sizing, market share, and forecasting, focusing instead on evidence-based drivers, constraints, regional patterns, and strategic implications for industry decision-makers.

Conclusion

Livestock medicine is entering a more preventive, data-enabled, and stewardship-driven era. Disease preparedness, vaccination, diagnostics, responsible antimicrobial use, animal welfare, and traceability are now central to livestock productivity and food-system resilience. Regional priorities differ, from high-standard regulatory compliance in Europe and North America to access expansion and disease-control needs across Asia-Pacific, Latin America, Africa, and the Middle East. Artificial intelligence and digital monitoring can strengthen veterinary decision-making when grounded in validated data and practical farm workflows. Organizations that align livestock medicine strategies with One Health principles, biosecurity, regulatory compliance, and producer-level usability will be best positioned to support healthier animals, safer food, and more resilient agricultural systems.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Livestock Medicine Market, by Product Type

• 7.1. Introduction
• 7.2. Anti-inflammatory Agents
• 7.3. Antibiotics
  • 7.3.1. Cephalosporins
  • 7.3.2. Penicillins
  • 7.3.3. Tetracyclines
• 7.4. Antiparasitic Agents
  • 7.4.1. Ectoparasiticides
  • 7.4.2. Endoparasiticides
• 7.5. Feed Additives
  • 7.5.1. Prebiotics
  • 7.5.2. Probiotics
• 7.6. Hormones
  • 7.6.1. Growth Hormones
  • 7.6.2. Reproductive Hormones
• 7.7. Vaccines
  • 7.7.1. Inactivated Vaccines
  • 7.7.2. Live Attenuated Vaccines
  • 7.7.3. Subunit Vaccines

8. Livestock Medicine Market, by Disease Type

• 8.1. Introduction
• 8.2. Infectious Diseases
• 8.3. Metabolic Diseases
• 8.4. Nutritional Deficiency Diseases
• 8.5. Parasitic Diseases
• 8.6. Reproductive Diseases

9. Livestock Medicine Market, by Animal Type

• 9.1. Introduction
• 9.2. Aquaculture
• 9.3. Cattle
• 9.4. Goats
• 9.5. Poultry
• 9.6. Sheep
• 9.7. Swine

10. Livestock Medicine Market, by Formulation

• 10.1. Introduction
• 10.2. Capsules
• 10.3. Gels
• 10.4. Liquids
• 10.5. Powders
• 10.6. Tablets

11. Livestock Medicine Market, by Route of Administration

• 11.1. Introduction
• 11.2. Inhalation
• 11.3. Injectable
  • 11.3.1. Intramuscular
  • 11.3.2. Intravenous
• 11.4. Oral
  • 11.4.1. Liquids
  • 11.4.2. Tablets
• 11.5. Topical
  • 11.5.1. Creams
  • 11.5.2. Patches

12. Livestock Medicine Market, by End Users

• 12.1. Introduction
• 12.2. Livestock Farmers
• 12.3. Veterinary Clinics
• 12.4. Veterinary Hospitals

13. Livestock Medicine Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Livestock Medicine Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Livestock Medicine Market, by Country

• 15.1. United States
• 15.2. Germany
• 15.3. China
• 15.4. United Kingdom
• 15.5. India
• 15.6. Japan
• 15.7. Russia
• 15.8. Brazil
• 15.9. Canada
• 15.10. Italy
• 15.11. Mexico
• 15.12. France
• 15.13. Spain
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. AdvaCare Pharma USA
• 17.2. Anicon Labor GmbH by SAN Group GmbH
• 17.3. AniCura Group by Mars Petcare
• 17.4. Bimeda Holdings Limited
• 17.5. Biogenesis Bago SA
• 17.6. Boehringer Ingelheim International GmbH
• 17.7. Calier Laboratories S.A.
• 17.8. Cargill, Incorporated
• 17.9. Ceva Sante Animale
• 17.10. Dechra Pharmaceuticals PLC
• 17.11. Elanco Animal Health Incorporated
• 17.12. HESTER BIOSCIENCES LIMITED
• 17.13. HIPRA S.A.
• 17.14. HUVEPHARMA EOOD
• 17.15. Indian Immunologicals Ltd.
• 17.16. Merck KGaA
• 17.17. Neogen Corporation
• 17.18. Norbrook Group
• 17.19. Parnell Pharmaceuticals Holdings Ltd.
• 17.20. Phibro Animal Health Corporation
• 17.21. Vetoquinol S.A.
• 17.22. Vetpharma Animal Health S.L.
• 17.23. Vetpro Healthcare
• 17.24. Virbac SA
• 17.25. Zoetis Inc.